Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19

NCT04900454 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Pneumonia

Interventions

BIOLOGICAL: DVX201

Sponsor

Coeptis Therapeutics

Collaborators

[object Object]